Drug Profile
Research programme: bradykinin B1 receptor antagonists - Fournier Pharma
Alternative Names: LF 20-0042; LF 521Latest Information Update: 24 Sep 2007
Price :
$50
*
At a glance
- Originator Fournier Pharma
- Class
- Mechanism of Action Bradykinin B1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Pain
Most Recent Events
- 28 Jul 2005 Fournier-Pharma has been acquired by Solvay
- 01 Jun 2005 This programme is still in active development for chronic pain management
- 30 May 2005 Preclinical trials in Pain in France (Parenteral)